JUAN BAUTISTA IRIBARREN
- Type
- Physician · Allopathic & Osteopathic Physicians / General Practice
- Where
- BEAUMONT, TX
- NPI
- 1720283336
- Received
- $915,403 in 1,047 records, 2019 to 2025
- As principal investigator
- $60,200 of research payments to others in 55 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 257 | $223,764 |
| 2024 | General payment | 231 | $259,635 |
| 2023 | General payment | 141 | $77,573 |
| 2022 | General payment | 90 | $81,684 |
| 2021 | General payment | 91 | $71,457 |
| 2020 | General payment | 121 | $111,946 |
| 2019 | General payment | 116 | $89,341 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 238 | $833,569 |
| Travel and Lodging | 109 | $47,087 |
| Food and Beverage | 686 | $20,068 |
| Consulting Fee | 9 | $14,492 |
| Education | 5 | $185 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-22 | Inspire Medical Systems, Inc. | $62 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-12-19 | Inspire Medical Systems, Inc. | $15 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-12-18 | AstraZeneca Pharmaceuticals LP | $109 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-12-17 | Baxter Healthcare | $21 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-12-17 | Viatris Specialty LLC | $20 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-12-17 | Insmed, Inc. | $11 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-12-16 | GlaxoSmithKline, LLC. | $8 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-12-09 | GENZYME CORPORATION | $3,672 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-09 | GENZYME CORPORATION | $125 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-12-09 | Insmed, Inc. | $23 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-11-26 | AstraZeneca Pharmaceuticals LP | $3,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-25 | AstraZeneca Pharmaceuticals LP | $1,320 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20 | Food and Beverage | In-kind items and services | JASCAYD Drug, RESPIRATORY | 2025 | |
| 2025-11-20 | AstraZeneca Pharmaceuticals LP | $3,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-20 | AstraZeneca Pharmaceuticals LP | $717 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-20 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-19 | Insmed, Inc. | $12 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-11-18 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-18 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-17 | GENZYME CORPORATION | $5,202 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-17 | GENZYME CORPORATION | $115 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-14 | Insmed, Inc. | $13 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-11-13 | AstraZeneca Pharmaceuticals LP | $3,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-13 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $1,760 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $844 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $183 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $119 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-12 | GlaxoSmithKline, LLC. | $20 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-11-10 | AstraZeneca Pharmaceuticals LP | $89 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-11-07 | Insmed, Inc. | $14 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $682 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $274 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $226 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-06 | AstraZeneca Pharmaceuticals LP | $107 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-11-05 | Actelion Pharmaceuticals US, Inc. | $22 | Food and Beverage | In-kind items and services | OPSYNVI Drug, Pulmonary Hypertension | 2025 | |
| 2025-11-04 | Regeneron Healthcare Solutions, Inc. | $19 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-04 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-11-04 | Regeneron Healthcare Solutions, Inc. | $1 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-03 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-30 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-30 | Verona Pharma, Inc. | $24 | Food and Beverage | Cash or cash equivalent | Ohtuvayre Drug, Pulmonary/Respiratory Diseases | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $7,956 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $562 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $270 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $159 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-29 | GENZYME CORPORATION | $98 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | JASCAYD Drug, RESPIRATORY | 2025 | |
| 2025-10-27 | Insmed, Inc. | $19 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-23 | AstraZeneca Pharmaceuticals LP | $694 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-23 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-10-16 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | TRELEGY ELLIPTA Drug, RESPIRATORY | 2025 | |
| 2025-10-16 | Insmed, Inc. | $3 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-10-14 | GENZYME CORPORATION | $24 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-10 | Regeneron Healthcare Solutions, Inc. | $612 | Consulting Fee | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $7,344 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $315 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $236 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-09 | GENZYME CORPORATION | $122 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-07 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-07 | AstraZeneca Pharmaceuticals LP | $200 | Travel and Lodging | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-07 | Viatris Specialty LLC | $19 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-10-04 | Regeneron Healthcare Solutions, Inc. | $6,426 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-04 | Regeneron Healthcare Solutions, Inc. | $1,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $139 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-02 | AstraZeneca Pharmaceuticals LP | $122 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-10-02 | GENZYME CORPORATION | $113 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-02 | GlaxoSmithKline, LLC. | $4 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-10-01 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-26 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-26 | Regeneron Healthcare Solutions, Inc. | $1,566 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-25 | Regeneron Healthcare Solutions, Inc. | $119 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-24 | AstraZeneca Pharmaceuticals LP | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-23 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-22 | ARS Pharmaceuticals Operations, Inc. | $14 | Food and Beverage | In-kind items and services | NEFFY Drug, ALLERGY | 2025 | |
| 2025-09-21 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | FASENRA Biological, Respiratory | 2025 | |
| 2025-09-19 | AstraZeneca Pharmaceuticals LP | $2,148 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-18 | GENZYME CORPORATION | $7,344 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $252 | Travel and Lodging | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $158 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $117 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-18 | GENZYME CORPORATION | $2 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-17 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-17 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $126 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-16 | AstraZeneca Pharmaceuticals LP | $116 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-16 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-09-15 | Insmed, Inc. | $17 | Education | In-kind items and services | Brinsupri Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $283 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $135 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $63 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $54 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $40 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-12 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $127 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-11 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-10 | AstraZeneca Pharmaceuticals LP | $68 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-10 | Viatris Specialty LLC | $23 | Food and Beverage | In-kind items and services | YUPELRI Drug, Anticholinergics, Inhaled | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-09 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $3,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $398 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $241 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $139 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-04 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-09-03 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-29 | Insmed, Inc. | $4 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-28 | AstraZeneca Pharmaceuticals LP | $104 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-28 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-28 | Baxter Healthcare | $17 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-08-27 | AstraZeneca Pharmaceuticals LP | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-27 | AstraZeneca Pharmaceuticals LP | $133 | Travel and Lodging | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-27 | AstraZeneca Pharmaceuticals LP | $81 | Food and Beverage | In-kind items and services | BREZTRI Drug, Respiratory | 2025 | |
| 2025-08-26 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-25 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-21 | AstraZeneca Pharmaceuticals LP | $152 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-21 | AstraZeneca Pharmaceuticals LP | $121 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-21 | Amgen Inc. | $34 | Education | In-kind items and services | 2025 | ||
| 2025-08-21 | AstraZeneca Pharmaceuticals LP | $18 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $156 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-20 | AstraZeneca Pharmaceuticals LP | $118 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-08-19 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-19 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-18 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-08-14 | Insmed, Inc. | $2 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-08-12 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-07 | AstraZeneca Pharmaceuticals LP | $109 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-03 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-08-01 | Insmed, Inc. | $4 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-07-31 | Baxter Healthcare | $26 | Food and Beverage | In-kind items and services | Hillrom - Vest System Model 105 Home Care Device, Airway Clearance Device | 2025 | |
| 2025-07-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-28 | Inspire Medical Systems, Inc. | $27 | Food and Beverage | In-kind items and services | INSPIRE Device, NEUROLOGY | 2025 | |
| 2025-07-28 | AstraZeneca Pharmaceuticals LP | $26 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-07-24 | GENZYME CORPORATION | $27 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-23 | GlaxoSmithKline, LLC. | $2 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-07-22 | Insmed, Inc. | $19 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-07-21 | AstraZeneca Pharmaceuticals LP | $14 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-07-21 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-07-11 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-11 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-07-02 | GENZYME CORPORATION | $7 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-19 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-18 | Insmed, Inc. | $22 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-06-16 | AstraZeneca Pharmaceuticals LP | $2,150 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $103 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-11 | AstraZeneca Pharmaceuticals LP | $30 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-10 | AstraZeneca Pharmaceuticals LP | $1,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-10 | GlaxoSmithKline, LLC. | $3 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-06-09 | AstraZeneca Pharmaceuticals LP | $3,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-09 | AstraZeneca Pharmaceuticals LP | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-09 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-06 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $4,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $103 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $40 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $38 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $32 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-05 | Insmed, Inc. | $20 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-06-05 | AstraZeneca Pharmaceuticals LP | $1 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-04 | AstraZeneca Pharmaceuticals LP | $129 | Travel and Lodging | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-06-04 | AstraZeneca Pharmaceuticals LP | $116 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-30 | Insmed, Inc. | $16 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-05-28 | GlaxoSmithKline, LLC. | $5 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 | |
| 2025-05-26 | AstraZeneca Pharmaceuticals LP | $450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-23 | Regeneron Healthcare Solutions, Inc. | $4,284 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-22 | AstraZeneca Pharmaceuticals LP | $102 | Food and Beverage | In-kind items and services | AIRSUPRA Drug, Respiratory | 2025 | |
| 2025-05-22 | GENZYME CORPORATION | $11 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-20 | Insmed, Inc. | $7 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-05-09 | GENZYME CORPORATION | $2,448 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-09 | GENZYME CORPORATION | $2,448 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $7,344 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $2,448 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $2,448 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $634 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $439 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-08 | GENZYME CORPORATION | $59 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-06 | Insmed, Inc. | $20 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-05-05 | Insmed, Inc. | $2 | Food and Beverage | In-kind items and services | Arikayce Drug, Respiratory | 2025 | |
| 2025-04-29 | GENZYME CORPORATION | $3,366 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-29 | Regeneron Healthcare Solutions, Inc. | $161 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-29 | Regeneron Healthcare Solutions, Inc. | $151 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-29 | Regeneron Healthcare Solutions, Inc. | $151 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-29 | GENZYME CORPORATION | $83 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-29 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | TEZSPIRE Biological, Respiratory | 2025 | |
| 2025-04-29 | GENZYME CORPORATION | $6 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-26 | Regeneron Healthcare Solutions, Inc. | $387 | Travel and Lodging | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-26 | Regeneron Healthcare Solutions, Inc. | $94 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-26 | Regeneron Healthcare Solutions, Inc. | $88 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-26 | Regeneron Healthcare Solutions, Inc. | $73 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-26 | Regeneron Healthcare Solutions, Inc. | $60 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-04-25 | GENZYME CORPORATION | $3,366 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-25 | GENZYME CORPORATION | $30 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-23 | GlaxoSmithKline, LLC. | $6 | Food and Beverage | In-kind items and services | NUCALA Biological, IMMUNOLOGY | 2025 |
The latest 200 records of 1,047.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $7 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2025 |
| 2025-07-30 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $944 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2025 |
| 2025-07-30 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,594 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2025 |
| 2024-06-12 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,661 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-05-17 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,389 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-05-17 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $944 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-05-17 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $944 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,375 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,661 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,389 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $944 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,727 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,389 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,389 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,655 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-04-05 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,456 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $28 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $28 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $28 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $28 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $28 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-03-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $17 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $100 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2024-01-04 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $43 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2024 |
| 2023-10-11 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,594 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,375 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,594 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $944 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,661 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,456 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,727 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,375 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-10-10 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $1,456 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-09-22 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $11,650 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
| 2023-09-01 | Dompe Farmaceutici S.p.A. | BAPTIST BEAUMONT HOSPITAL | $14,236 | Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and saf | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Beaumont, TX, county Jefferson County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Beaumont, TX | County Jefferson County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 113,279 | 253,878 | 30,188,424 |
| Population, 2020 census P1 | 115,282 | 256,526 | 29,145,505 |
| Median age B01002 | 35.3 | 37.0 | 35.6 |
| Under 18 B01001 | 25.3% | 24.6% | 25.0% |
| 65 and over B01001 | 16.3% | 15.5% | 13.4% |
| Households B11001 | 45,001 | 94,807 | 10,992,816 |
| Foreign born B05002 | 11.0% | 12.1% | 17.6% |
| Median household income B19013 | $56,997 | $60,026 | $78,476 |
| Median family income B19113 | $71,096 | $75,099 | $94,599 |
| Per capita income B19301 | $32,642 | $32,101 | $40,752 |
| Poverty rate B17001 | 21.2% | 19.5% | 13.8% |
| Unemployment rate B23025 | 6.4% | 6.3% | 5.3% |
| Civilian labor force B23025 | 52,630 | 110,898 | 15,233,563 |
| Mean commute (minutes) B08013 | 20.3 | 21.2 | 26.7 |
| Bachelor's degree or higher B15003 | 24.9% | 19.7% | 33.8% |
| Housing units B25001 | 52,439 | 109,884 | 12,128,515 |
| Owner-occupied B25003 | 55.3% | 62.5% | 62.6% |
| Renters B25003 | 44.7% | 37.5% | 37.4% |
| Median home value B25077 | $166,400 | $169,500 | $283,800 |
| Median gross rent B25064 | $1,121 | $1,117 | $1,403 |
| White, not Hispanic B03002 | 26.3% | 36.3% | 39.1% |
| Black B03002 | 45.2% | 32.7% | 11.9% |
| Hispanic or Latino B03002 | 20.8% | 24.1% | 39.7% |
| Asian B03002 | 3.8% | 3.8% | 5.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Beaumont, TX.
Comments